FRESENIUS SE & CO. KGAA | Factsheet Q1 - Q3 / 22
COMPANY PROFILE
Fresenius is a global health care group providing products and services for dialysis, hospitals and outpatient medical care. In addition, Frese- nius focuses on hospital operations. We also manage projects and provide services for hospitals and other health care facilities. More than 300,000 employees have dedicated themselves to the service of health in over 100 countries worldwide.
FRESENIUS GROUP IN FIGURES
€ in millions | Q1 - Q3/22 | Q1 - Q3/21 | Change | FY / 21 | |||||
Sales and Earnings | |||||||||
Sales | 30,197 | 27,554 | 10% | 37,520 | |||||
EBIT 1 | 2,952 | 3,086 | -4% | 4,252 | |||||
Net income 1, 2 | 1,284 | 1,346 | -5% | 1,867 | |||||
Earnings per share in € 1, 2 | 2.29 | 2.41 | -5% | 3.35 | |||||
Balance sheet and cash flow | |||||||||
Total assets | 80,328 | 12% | 71,962 | ||||||
Non-current assets | 60,885 | 12% | 54,501 | ||||||
Equity 3 | 34,156 | 17% | 29,288 | ||||||
Equity ratio 3 | 42.5% | 40.7% | |||||||
Net debt / EBITDA 1, 4 | 3,74x | 3.51 | |||||||
Investments 5 | 2,128 | 2,149 | -1% | 3,117 | |||||
Operating cash flow | 2,374 | 3,329 | -29% | 5,078 | |||||
Operating cash flow in % | |||||||||
of sales | 7.9% | 12.1 % | 13.5% | ||||||
Profitability | |||||||||
EBIT margin 1 | 9.8% | 11.2% | 11.3% | ||||||
Return on equity after taxes | |||||||||
(ROE) 1, 2 | 8.4% | 10.1% | 9.8% | ||||||
Return on operating assets | |||||||||
(ROOA) 1 | 5.7% | 6.6% | 6.5% | ||||||
Return on invested capital | |||||||||
(ROIC) 1 | 5.1% | 6.1% | 5.9% | ||||||
Employees | 319,691 | 316,078 | |||||||
- Before special items
- Net income attributable to shareholders of Fresenius SE & Co. KGaA
- Including noncontrolling interests
- At LTM average exchange rates for both net debt and EBITDA; pro forma closed acquisitions / divestitures
- Investments in property, plant and equipment, and intangible assets, acquisitions
GROUP STRUCTURE
The operating business comprises the four business segments, all of which are legally independent entities managed by the operating parent company Fresenius SE & Co. KGaA.
32% 1 | 100% | 100% | 77% | |||||||||||||
Fresenius | Fresenius | Fresenius | Fresenius | |||||||||||||
Medical Care | Kabi | Helios | Vamed | |||||||||||||
1 As of September 30, 2022
BUSINESS SEGMENTS
€ in millions | Q1 - Q3/22 | Q1 - Q3/21 | Change | FY/ 21 | ||||||
Sales | 14,401 | 12,972 | 11% | 17,619 | ||||||
EBIT 1 | 1,160 | 1,403 | - 17% | 1,852 | ||||||
Sales | 5,814 | 5,370 | 8% | 7,193 | ||||||
EBIT 2 | 844 | 874 | - 3% | 1,153 | ||||||
Sales | 8,685 | 8,009 | 8% | 10,891 | ||||||
EBIT 2 | 831 | 788 | 5% | 1,127 | ||||||
Sales | 1,647 | 1,549 | 6% | 2,297 | ||||||
EBIT 2 | 29 | 35 | -17% | 101 | ||||||
1 Reported
2 Before special items
SALES BY REGION
Latin America and
Others 6%
Asia-Pacific10%
Europe 44%
North America 40%
Q1 - Q3 / 22: € 30.2 billion
- Fresenius Medical Care is the world's largest provider of products and services for individuals with renal diseases. As of September 30, 2022, Fresenius Medical Care was treating 344,593 patients in 4,153 dialysis clinics. Along with its core business, the Renal Care Continuum, the company focuses on expanding in complementary areas and in the field of critical care.
- Fresenius Kabi offers intravenously administered generic drugs,
clinical nutrition and infusion therapies for seriously and chroni- cally ill patients in the hospital and outpatient environments. The company is also a leading supplier of medical devices and transfusion technology products. In the biosimilars business, Fresenius Kabi develops products with a focus on oncology and autoimmune diseases. - Fresenius Helios is Europe's leading private hospital operator. The company comprises Helios Germany, Helios Spain and Helios Fertility. Helios Germany operates 87 hospitals, ~130 outpatient centers and 6 prevention centers. Helios Spain operates 50 hospitals, 101 outpatient centers and around 300 occupational risk preven- tion centers. In addition, the company is active in Latin America with 8 hospitals and as a provider of medical diagnostics. Helios Fertility offers a wide spectrum of state-of-the-art services in the field of fertility treatments.
- Fresenius Vamed manages projects and provides services for hos- pitals and other health care facilities worldwide and is a leading post-acute care provider in Central Europe. The portfolio ranges along the entire value chain: from project development, planning, and turnkey construction, via maintenance and technical manage- ment to total operational management.
SALES BY BUSINESS SEGMENT
Fresenius Vamed
5%
Fresenius Kabi
19%
Fresenius Medical Care
47%
Fresenius Helios
29%
Q1 - Q3 / 22: € 30.2 billion
Factsheet Q1 - Q3 / 22 © Fresenius SE & Co. KGaA - Investor Relations & Sustainability
| Factsheet Q1 - Q3 / 22
RELATIVE SHARE PRICE PERFORMANCE
FRESENIUS SHARE VS. DAX
110
100
90
80
70
60
50 | ||||||||||||
30.12.2021 | 31.01.2022 | 28.02.2022 | 31.03.2022 | 30.04.2022 | 31.05.2022 | 30.06.2022 | 29.07.2022 | 01.09.2022 | 30.09.2022 | |||
DAX | Fresenius share | |||||||||||
DEVELOPMENT OF DIVIDENDS IN €
0.88 | 0.92 | ||||||||
0.84 | |||||||||
0.80 | |||||||||
0.75 | |||||||||
0.62 | |||||||||
0.55 | |||||||||
0,42 | 0.44 | ||||||||
0.37 | |||||||||
2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
GROUP OUTLOOK 2022
FY / 21 Base1 | Targets 2022 2 | |||
Low-to-mid | ||||
single-digit per- | ||||
Sales, growth (cc) | €37,520 million | centage growth | ||
Decline of | ||||
Net income 3, growth (cc) | €1,867 milion | around 10% | ||
- Before special items, including COVID-19 effects
- Before special items, including estimated COVID-19 effects
- Net income attributable to shareholders of Fresenius SE & Co. KGaA
For the outlook of the business segments please see the Investor News of October 30, 2022.
FRESENIUS SHARE / ADR | ANALYST RECOMMENDATIONS | FINANCING MIX OF THE FRESENIUS GROUP |
Sustainability
Share
Securities code no. | 578 560 | ||||
ISIN | DE0005785604 | ||||
Equal-weight / Hold / | |||||
Ticker symbol | FRE | ||||
Neutral | 50% | ||||
ADR CUSIP | 35804M105 | ||||
ADR Ticker symbol | FSNUY | ||||
Number of shares (September 30, 2022) | 563,237,277 | ||||
Market capitalization (September 30, 2022) | €12.4 billion | As of September 30, 2022 |
Buy /Outperform / Overweight 50%
Equity-neutral convertible bonds 2 %
Commercial Paper 3%
Other financial liabilities 5%
Schuldschein loans 6%
Lease liabilities 25%
EIB loan 1%
Bonds 58%
KGaA - Investor Relations &
September 30, 2022: ~ € 28.6 billion
FINANCIAL CALENDAR | CONTACT | |||
Dates | ||||
Report on Fiscal Year 2022 | February 22, 2023 | |||
Report on 1st quarter 2023 | May 9, 2023 | |||
Annual General Meeting | May 17, 2023 | |||
Report on 1st half 2023 | August 2, 2023 | |||
Report on 1st- 3rd quarter 2023 | November 1, 2022 | |||
Please note that these dates could be subject to modifications.
www.fresenius.com/events-and-roadshows
Fresenius SE & Co. KGaA Else-Kröner-Straße1, 61352 Bad Homburg v. d. H. E-mail: ir-fre@fresenius.com
Internet: www.fresenius.de
Markus Georgi
Senior Vice President
Investor Relations & Sustainability
Telephone: +49 (0 ) 61 72 / 6 08-24 85
Telefax: +49 (0 ) 61 72 / 6 08-24 88
Follow us on Social Media:
linkedin.com/company/fresenius-investor-relations
twitter.com/Fresenius_IR
For more information please see the imprint on our corporate website.
Factsheet Q1 - Q3 / 22 © Fresenius SE & Co.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Fresenius SE & Co. KGaA published this content on 04 November 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 04 November 2022 15:11:03 UTC.
